Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 5, 2002, Pages 1329-1335

  Smee, Donald F ^a   Sidwell, Robert W ^a   Kefauver, Debbie ^a   Bray, Mike ^a   Huggins, John W ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 HYDROXY 2 PHOSPHONYLMETHOXYPROPYL)ADENINE; 3 DEAZAARISTEROMYCIN; ANTIVIRUS AGENT; CIDOFOVIR; CIDOFOVIR DIPHOSPHATE; CYTARABINE TRIPHOSPHATE; DNA POLYMERASE; MYCOPHENOLIC ACID; RIBAVIRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; CAMELPOX VIRUS; CELL STRAIN 3T3; CONCENTRATION RESPONSE; CONTROLLED STUDY; COWPOX VIRUS; CROSS RESISTANCE; DRUG EFFICACY; ENZYME INHIBITION; MORTALITY; MOUSE; NONHUMAN; PHOSPHORYLATION; POXVIRUS; POXVIRUS INFECTION; PRIORITY JOURNAL; STRAIN DIFFERENCE; VACCINIA VIRUS; VERO CELL; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE; WILD TYPE;

3T3 CELLS; ANIMALS; ANTIVIRAL AGENTS; CAMELS; CATTLE; CERCOPITHECUS AETHIOPS; COWPOX VIRUS; CYTOSINE; DRUG RESISTANCE, VIRAL; MICE; MICE, INBRED BALB C; MICE, SCID; MICROBIAL SENSITIVITY TESTS; MONKEYPOX VIRUS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PLAQUE ASSAY; POXVIRIDAE; POXVIRIDAE INFECTIONS; VACCINIA VIRUS; VERO CELLS; VIRUS REPLICATION;

EID: 0036239724     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.5.1329-1335.2002     Document Type: Article

References (35)

1. Kinetics and intermediates in the intracellular synthesis of bacteriophage T4 deoxyribonucleic acid
2. Differential susceptibility of several drug-resistant strains of herpes simplex virus type 2 to various antiviral compounds
3. Ganciclovir-resistant human cytomegalovirus clinical isolates; resistance mechanisms and in vitro susceptibility to antiviral agents
4. 1-[((S)-2-Hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo
5. Cidofovir (HPMPC) protects mice against lethal aerosol or intranasal cowpox virus challenge
6. Poxvirus dilemmas-monkeypox, smallpox and biological terrorism
7. 50) of an enzymatic reaction
8. Biochemical and genetic analysis of acyclovir-resistant mutants of herpes simplex virus type 1
9. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo
10. Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine
11. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents
12. Field trials of methisazone as a prophylactic agent against smallpox
13. Re-emergence of monkeypox in Africa: A review of the past six years
14. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis
15. Progressive vaccinia treated with ribavirin and vaccinia immune globulin
16. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents
17. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir
18. Genetic evidence for vaccinia virus-encoded DNA polymerase: Isolation of phosphonoacetate-resistant enzyme from the cytoplasm of cells infected with mutant virus
19. Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse
20. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice
21. Metabolism of ganciclovir and cidofovir in cells infected with drug-resistant and wild-type strains of murine cytomegalovirus
22. The importance of IMP dehydrogenase inhibition in the broad spectrum antiviral activity of ribavirin and selenazofurin
23. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir
24. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir
25. Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus
26. Mode of action of ribavirin against cowpox and monkeypox viruses
27. Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine
28. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives
29. Genetic characterization of the vaccinia virus DNA polymerase: Cytosine arabinoside resistance requires a variable lesion conferring phosphonoacetate resistance in conjunction with an invariant mutation localized to the 3′-5′ exonuclease domain
30. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors
31. Mutations occur in highly conserved domains of murine cytomegalovirus DNA polymerase in cidofovir- and lobucavir-resistant strains
32. Topical cidofovir: A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1
33. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase